AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP Form_NN 20-F_NNP Information_NNP 2004_CD 97_CD 22_CD Net_JJ cash_NN inflow_NN from_IN trading_NN operations_NNS 2004 2003 2002_CD $_$ m_CD $_$ m_CD $_$ m_CD Operating_NN profit_NN before_IN exceptional_JJ items_NNS 4,770_CD 4,111_CD 4,356_CD Depreciation_NN ,_, amortisation_NN and_CC impairment_NN 1,268_CD 1,290_CD 960_CD Stocks_NNS decrease_VBP increase_NN 129 131 101_CD Debtors_NNS increase_NN 209 540 198_CD Creditors_NNS increase_NN decrease_NN 71 430 402_CD Other_JJ non-cash_JJ movements_NNS including_VBG exchange_NN 40_CD 317_CD 65_CD 6,069_CD 4,617_CD 5,686_CD 23_CD Cash_NN outflow_NN related_VBN to_TO exceptional_JJ items_NNS 2004 2003 2002_CD Current_JJ period_NN cash_NN flow_NN related_VBN to_TO exceptional_JJ items_NNS $_$ m_CD $_$ m_CD $_$ m_CD Synergy_NNP and_CC integration_NN costs_NNS 25_CD 68_CD Zoladex_NNP OIG_NNP settlement_NN 355_CD Costs_NNS relating_VBG to_TO disposals_NNS and_CC demerger_NN of_IN other_JJ businesses_NNS 8_CD 11_CD 25_CD Outflow_NN related_VBN to_TO exceptional_JJ items_NNS 8_CD 391_CD 93_CD Details_NNS of_IN the_DT cash_NN inflows_NNS in_IN connection_NN with_IN the_DT profit_NN on_IN the_DT sale_NN of_IN an_DT interest_NN in_IN a_DT joint_JJ venture_NN are_VBP set_VBN out_RP in_IN Note_NN 24_CD ._.
24_CD Disposal_NN of_IN business_NN operations_NNS 2004 2003 2002_CD $_$ m_CD $_$ m_CD $_$ m_CD Fixed_VBN assets_NNS 2_CD 70_CD Current_JJ assets_NNS 17_CD 34_CD Creditors_NNS due_JJ within_IN one_CD year_NN 7_CD 17_CD Book_NN value_NN of_IN net_JJ assets_NNS disposed_VBD 12_CD 87_CD Disposal_NN costs_NNS 72_CD Profit_NN on_IN disposals_NNS 274_CD Less_RBR :_: Cash_NN included_VBD in_IN undertakings_NNS disposed_VBD 3_CD 7_CD Cash_NN consideration_NN 355_CD 80_CD The_DT cash_NN consideration_NN is_VBZ in_IN relation_NN to_TO the_DT sale_NN of_IN the_DT Groups_NNS share_NN of_IN the_DT joint_JJ venture_NN Advanta_NNP BV_NNP ,_, which_WDT was_VBD completed_VBN on_IN 1_CD September_NNP 2004_CD $_$ 284m_CD and_CC the_DT disposal_NN of_IN the_DT Durascan_JJ business_NN in_IN the_DT first_JJ half_NN of_IN the_DT year_NN $_$ 71m_CD ._.
The_DT profit_NN on_IN disposal_NN is_VBZ stated_VBN after_IN transaction_NN costs_NNS and_CC warranty_NN provisions_NNS ._.
The_DT sale_NN consideration_NN received_VBN in_IN 2003_CD was_VBD in_IN relation_NN to_TO the_DT sale_NN of_IN Marlow_NNP Foods_NNP Limited_NNP ,_, which_WDT was_VBD completed_VBN on_IN 23_CD May_NNP 2003_CD ._.
